Nicolas Sabarth is heading a biotherapeutics discovery group at Boehringer-Ingelheim Vienna, Austria. He received his PhD from the Max-Planck-Institute for Infection Biology, Germany. Since then, he held positions of increasing responsibility in the R&D departments of GlaxoSmithKline, Intercell, and Baxalta. He is a drug discovery professional with emphasis on innovate biotherapeutics in immuno-oncology, immunology and oncology. His expertise is therapeutic concept validation, antibody discovery, and antibody engineering. In particular, multispecific antibody concepts and T cell engagers are at the center of his research